XML 52 R33.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Quarterly Financial Data (Unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 28, 2018
Quarterly Financial Information Disclosure [Abstract] |
Schedule of Quarterly Financial Data | The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):
| Quarter Ended
| December 31, |  | September 30, |  | June 30, |  | March 31,
2018: |  |  |  |  |  |  |
Total revenues (1) | $ | 228,602 |  |  | $ | 225,397 |  |  | $ | 186,108 |  |  | $ | 213,719 |
Gross profit (2) | $ | 168,873 |  |  | $ | 155,586 |  |  | $ | 139,839 |  |  | $ | 128,633 |
Income from operations | $ | 111,602 |  |  | $ | 125,176 |  |  | $ | 85,770 |  |  | $ | 116,307 |
Net income | $ | 360,089 |  |  | $ | 126,630 |  |  | $ | 87,494 |  |  | $ | 115,857 |
Net income per share, basic | $ | 1.20 |  |  | $ | 0.42 |  |  | $ | 0.29 |  |  | $ | 0.39 |
Net income per share, diluted | $ | 1.15 |  |  | $ | 0.41 |  |  | $ | 0.28 |  |  | $ | 0.37 |
2017: |  |  |  |  |  |  |
Total revenues | $ | 120,072 |  |  | $ | 152,510 |  |  | $ | 99,008 |  |  | $ | 80,887 |
Gross profit (2) | $ | 91,520 |  |  | $ | 91,758 |  |  | $ | 84,990 |  |  | $ | 65,674 |
Income from operations | $ | 37,431 |  |  | $ | 81,180 |  |  | $ | 27,113 |  |  | $ | 20,186 |
Net income | $ | 38,489 |  |  | $ | 81,382 |  |  | $ | 17,656 |  |  | $ | 16,700 |
Net income per share, basic | $ | 0.13 |  |  | $ | 0.28 |  |  | $ | 0.06 |  |  | $ | 0.06 |
Net income per share, diluted | $ | 0.12 |  |  | $ | 0.26 |  |  | $ | 0.06 |  |  | $ | 0.05 |
____________________
(1) | Total revenues for the three months ended March 31, 2018 have been adjusted to reflect the reclassification of the $1.4 million profit related to the profit sharing arrangement with Genentech for the commercialization of COTELLIC. For three months ended March 31, 2018, the net profit had been classified as Selling, general and administrative expenses as we were expecting an overall loss for the year ended December 31, 2018. During the three months ended June 30, 2018, we determined that the U.S. commercialization of COTELLIC would result in a profit for the year ended December 31, 2018 and therefore, we reclassified the profit for the three months ended March 31, 2018 from Selling, general and administrative expenses to Collaboration revenues to be consistent with presentation for the three and six months ended June 30, 2018. See “Note 3. Collaboration Agreements” for more information on our collaboration agreement with Genentech.
(2) | Gross profit is computed as Net product revenues less Cost of goods sold.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration